Pfizer-Biocon biosimilar deal to set off many more

21 Oct 2010 Evaluate

The world’s largest drug maker Pfizer's first biosimilar (a medicine comparable to the original biotech drug) deal with India’s Biocon will trigger a new wave of outsourcing deals and acquisitions by multinational drug makers in India.Domestic companies that may benefit are believed to include biotech specialists and vaccine makers such as Panacea Biotec, Reliance Life Sciences, Bharat Biotech, BV Corp and Serum Institute of India, beside drug majors such as Wockhardt, Dr Reddy's Laboratories, Intas Biopharmaceuticals and Lupin, which are developing a large portfolio of biotech drugs.

 

The generic opportunity for biotech drugs such as EPO (for chemotherapy and renal failure), GCSF (prescribed to make more white blood cells during cancer treatment), Interferon Alpha (for Hepatitis C and renal failure), Interferon Beta (to treat multiple sclerosis, a chronic disease that affects central nervous system) and human insulin is estimated at $7 billion in Europe alone by 2015. These drugs are expected to be a $12-bn opportunity in the US market by 2015 and $25 bn in Europe. In India alone, biotech drugs are likely to generate revenues of $580 million (Rs 2,570 crore) by 2012, according to various estimates.

crackcrack

Pfizer Share Price

4266.90 -31.95 (-0.74%)
10-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1505.20
Dr. Reddys Lab 5922.45
Cipla 1339.45
Zydus Lifesciences 983.05
Lupin 1609.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.